Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PTC Wins NIH Grant | Contract Pharma

What are you searching for?

Sign in
Breaking News

PTC Wins NIH Grant

Supports discovery of antiviral agents for dengue fever

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PTC Therapeutics has received a $1 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) for the discovery of antiviral agents for the treatment of dengue fever. The one-year grant will support research for promising compounds identified by PTC’s proprietary GEMS (Gene Expression Modulation by Small-molecules) technology that demonstrate activity against the dengue virus (DENV).
 
PTC has established a cell-based DENV assay to screen a series of small molecules aimed at inhibiting key components of the virus. The goal of the NIH grant is to develop the first oral therapy to treat dengue.
 
“We are honored to receive this grant from the NIH, which is an important validation of the applicability of PTC’s science,” said Stuart W. Peltz, Ph.D., chief executive officer, PTC Therapeutics, Inc. “There are currently no treatments specifically targeting dengue and the disease represents a growing global health concern.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics